Welcome to CSL’s Open Innovation Submission Portal
CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives. Innovation has been in CSL’s DNA for more than a century. CSL has the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. Their strengths enable them to accurately identify, successfully develop, and dependably deliver innovations for patients.
At CSL they believe that for innovation to be fast tracked, they need to partner with the brightest minds in the sector. They know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and they collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients’ unmet needs around the globe.
If you have an idea related to new products, new technologies or new advancements relating to CSL’s areas of interest, please feel free to share it via the Submission Form. All submissions will be screened by yet2 and if successful, will be shared with CSL. Initial submissions should not include any confidential information.
Core interests for early stage partnering
CSL’s mission is to discover, develop and deliver our innovative therapies that improve the patients’ quality of life while maintaining the highest product safety standards and continually improving manufacturing effectiveness. We know that partnerships can accelerate innovation and delivery of new unique technologies, assets, and equipment, to address patients’ unmet needs around the globe. Below you will find our current interest areas where we seek innovative ideas that can improve our processes, equipment, and analytical capabilities within our three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapies.
Description
CSL seeks ways to rapidly remove dissolved inorganic (salts) ions from protein solutions in a manner that can be coupled with current and future processes.
Background
Methods such as chromatography and TFF require significant buffer volumes, are less adaptable to continuous processing, and can often increase cycle times. These steps also require extensive cleaning and regeneration processes, which prevent continuous equipment utilization. Being able to selectively remove inorganic ions, in a rapid manner, could allow for rapid transition from one process step to the next without having to undergo a significant processing step only required to reduce inorganic salt concentration.
Key Success Criteria
- ≥ 80% reduction in the inorganic salt concentration
- ≤ 5% loss of protein
- Rapid
- Scalable
- Potentially Adaptable to Continuous Processing
- Minimal Capital / Utility Needs
- Environmentally Friendly
Preferred Collaboration types
CSL and its affiliates are open to a range of collaboration types in this area.
Submit your solution here.
Image by Freepik